Imperial College London

Dr Robin Carhart-Harris

Faculty of MedicineDepartment of Brain Sciences

Research Fellow



+44 (0)20 7594 7992r.carhart-harris




Miss Bruna Cunha +44 (0)20 7594 7992




Burlington DanesHammersmith Campus






BibTex format

author = {Carhart-Harris, RL and Goodwin, GM},
doi = {10.1038/npp.2017.84},
journal = {Neuropsychopharmacology},
pages = {2105--2113},
title = {The therapeutic potential of psychedelic drugs: past, present and future},
url = {},
volume = {42},
year = {2017}

RIS format (EndNote, RefMan)

AB - Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.
AU - Carhart-Harris,RL
AU - Goodwin,GM
DO - 10.1038/npp.2017.84
EP - 2113
PY - 2017///
SN - 1740-634X
SP - 2105
TI - The therapeutic potential of psychedelic drugs: past, present and future
T2 - Neuropsychopharmacology
UR -
UR -
VL - 42
ER -